Home » Topics » BioWorld Science

BioWorld Science
RSS

HPN-328 targeting DLL3 shows preclinical efficacy and safety for immunotherapy in SCLC

Nov. 18, 2019

Roche presents first-in-human data for RO-7062931

Nov. 18, 2019

resTORbio stops development of RTB-101 for clinically symptomatic respiratory illness

Nov. 15, 2019

Interim data presented from phase I study of TK-216 in Ewing's sarcoma

Nov. 15, 2019

FDA grants accelerated approval to Brukinsa for mantle cell lymphoma

Nov. 15, 2019

FDA approves Fetroja for complicated urinary tract infections

Nov. 15, 2019

I-Mab obtains Chinese IND clearance for phase I trials of TJM-2 in rheumatoid arthritis

Nov. 15, 2019

Phase II study of AV-101 in major depressive disorder does not meet primary endpoint

Nov. 15, 2019

Results from SILK cohort evaluating tesevatinib in ADPKD patients presented at Kidney Week

Nov. 15, 2019

New IDO-1 inhibitors identified at Phenex Discovery Verwaltungs

Nov. 15, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...